Glaxosmithkline Plc (GSK) 46.59 $GSK
If You Live in This State, You May Lose the Choice Whether to Vaccinate Your Kids
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 26, 8:11AM CDT
Source: California State Legislature. California could make it a whole heck of a lot tougher for parents and guardians to choose whether to have their children vaccinated. The Golden State is considering legislation barring the use of the "personal...
MRK: 57.60 (+0.09), GSK: 46.59 (+0.28)
7 Top Dividend Sector Dogs Fetch 24% To 50% April Upsides
Fredrik Arnold - at Seeking Alpha - Fri Apr 24, 5:23PM CDT
NMFC: 14.93 (-0.03), RSO: 4.50 (+0.01), TIS: 22.16 (-1.43), NMM: 13.04 (+0.13), CPLP: 9.61 (+0.16), PER: 8.12 (+0.15), SFL: 15.63 (-0.01), TICC: 6.86 (-0.03), CNSL: 21.30 (+0.12), GSK: 46.59 (+0.28), WIN: 7.83 (-0.46), DSWL: 1.91 (unch), CPAC: 6.98 (-0.03), STB: 5.70 (-0.01), RIG: 16.40 (-0.57), MAT: 30.20 (+1.28), ARR: 3.16 (-0.02), XIN: 3.44 (-0.08), WMC: 14.91 (+0.07), SPKE: 13.00 (-0.04)
'Non-Cyclical Consumer Healthcare': How This Sector Will Create Long-Term Wealth
Peter Mantas - Seeking Alpha - Fri Apr 24, 1:39PM CDT
Allow me to provide you with a hypothetical portfolio containing only 5 stocks. This portfolio is somewhat diversified in that each company operates in different markets with different threats, competitors and opportunities, but all 5 companies have...
MCK: 229.20 (+0.09), AKRX: 55.24 (-0.68), PFE: 35.27 (-0.09), EW: 138.33 (-3.59), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), MOH: 63.85 (-0.13), ORCL: 43.08 (-0.31), CNC: 73.67 (+1.13), JNJ: 101.08 (+0.62), ANTM: 154.28 (+0.08), VRSK: 72.68 (+0.20), GILD: 103.69 (-1.52), RMD: 65.70 (-7.68), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), FICO: 93.85 (+0.55), WCN: 46.52 (+0.32), SRCL: 136.94 (-3.56), SNY: 51.75 (-0.01), ACN: 93.40 (-0.44), NVS: 104.28 (-1.22)
Why Agenus Inc. Shares Are Soaring Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 24, 1:04PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Agenus shot higher by more...
AGEN: 7.12 (+0.75), INCY: 107.34 (-0.51), GSK: 46.59 (+0.28)
Zofran Nationwide Class Action Lawsuit Under Consideration By Moll Law Group
PR Newswire - Fri Apr 24, 12:18PM CDT
A Chicago law firm said today it is considering filing the first nationwide class action lawsuit against GlaxoSmithKline (GSK), the makers of Zofran, a powerful anti-nausea drug alleged to increase the risk of birth defects when used by pregnant women, particularly during the first trimester.
GSK: 46.59 (+0.28)
No Hiding From Respirageddon For Boehringer
EP Vantage - Seeking Alpha - Fri Apr 24, 11:49AM CDT
Given the hammering that US prices of respiratory drugs have taken as payers assaulted GlaxoSmithKline ’s (NYSE: GSK ) Advair it might come as a shock that sales of Boehringer Ingelheim ’s blockbuster Spiriva fell just...
ABBV: 66.07 (+1.82), GSK: 46.59 (+0.28)
High-Yield Placeholders For Dividend Champions
Fast Track to Financial Independence - at Seeking Alpha - Fri Apr 24, 10:29AM CDT
KO: 40.89 (-0.06), MMM: 158.99 (-0.67), HTGC: 13.97 (-0.09), MAIN: 31.39 (+0.09), SDIV: 24.18 (+0.22), ED: 62.50 (+0.40), TGH: 31.32 (unch), GSK: 46.59 (+0.28), BNS: 54.97 (-0.01), MORL: 20.47 (+0.08), STWD: 24.27 (+0.10), T: 34.01 (-0.22), JNJ: 101.08 (+0.62), OHI: 38.53 (+0.24), PFF: 40.05 (+0.01), PG: 81.00 (+0.05), AIG: 56.99 (+0.24), AAPL: 130.28 (+0.61), BBL: 47.75 (+1.40), GAIN: 7.56 (-0.03)
Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 9:00AM CDT
Novartis' core earnings earnings per share came in at $1.33, down from $1.35 in the year-ago period but above the Zacks Consensus Estimate of $1.09.
SHPG: 255.11 (-0.26), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Glaxo's malaria vaccine candidate reduced cases in young children 36% in study
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 8:34AM CDT
GSK: 46.59 (+0.28)
GSK's Malaria Vaccine Phase 3 Study Containing Agenus' QS-21 Published in The Lancet
Business Wire - Fri Apr 24, 6:00AM CDT
--EMA currently reviewing the regulatory application
AGEN: 7.12 (+0.75), GSK: 46.59 (+0.28)
Novartis EPS beats the Street
at Investor's Business Daily - Thu Apr 23, 5:33PM CDT
The drugmaking giant earned $1.29 a share in Q1, up 0.8% from a year earlier, beating views by 19 cents. Novartis' (NVS) net profit quadrupled to $13 bil due to gains on sales of units to Eli Lilly (LLY) and GlaxoSmithKline (GSK). Revenue fell 15% to...
LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Isis Pharmaceuticals' ISIS-TTR Effective in Extension Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 5:21PM CDT
Isis Pharmaceuticals, Inc. (ISIS) announced positive data from an extension study on ISIS-TTR for familial amyloid polyneuropathy.
BIIB: 401.71 (-28.57), ISIS: 66.37 (-1.38), AVEO: 1.92 (-0.08), GSK: 46.59 (+0.28)
Novartis (NVS) Beats on Earnings & Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 2:05AM CDT
Novartis (NVS) Beats on Earnings & Revenues
GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Divestment gains boost net earnings at drug company Novartis
AP - Thu Apr 23, 1:57AM CDT
FRANKFURT, Germany (AP) — Swiss-based pharmaceutical company Novartis reported a large jump in first-quarter net profit Thursday as it recorded one-time gains from deals with other drug companies.
LLY: 71.58 (-0.82), GSK: 46.59 (+0.28)
SmarTrend Watching for Potential Rebound in Shares of GlaxoSmithKline After 1.42% Loss
Comtex SmarTrend(R) - Wed Apr 22, 4:37PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $46.43 to a high of $46.90. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $47.00 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 46.59 (+0.28)
GlaxoSmithKline Falls 1.42% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Apr 22, 4:37PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $46.43 to a high of $46.90. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $47.00 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 46.59 (+0.28)
Moll Law Group Considering First Nationwide Class Action Suit Against Maker Of Anti-Nausea Drug Zofran
PR Newswire - Wed Apr 22, 11:15AM CDT
A Chicago law firm said today it is considering filing the first nationwide class action suit against GlaxoSmithKline (GSK), the makers of Zofran, a powerful anti-nausea drug alleged to increase the risk of birth defects when used by pregnant women, particularly during the first trimester.
GSK: 46.59 (+0.28)
GlaxoSmithKline (GSK) Roof Leaking Today
at The Street - Wed Apr 22, 9:21AM CDT
Trade-Ideas LLC identified GlaxoSmithKline (GSK) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
GSK: 46.59 (+0.28)
Rising Rates? Don't Hold Your Breath
Yieldpig - at Seeking Alpha - Wed Apr 22, 4:32AM CDT
HTGC: 13.97 (-0.09), MAT: 30.20 (+1.28), GSK: 46.59 (+0.28)
Rhabdomyosarcoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 22, 3:50AM CDT
The report "Rhabdomyosarcoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Rhabdomyosarcoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/rhabdomyosar...eport.html.
MACK: 13.42 (-0.25), GSK: 46.59 (+0.28), CELGZ: 2.76 (-0.12)
If You Live in This State, You May Lose the Choice Whether to Vaccinate Your Kids
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 26, 8:11AM CDT
Source: California State Legislature. California could make it a whole heck of a lot tougher for parents and guardians to choose whether to have their children vaccinated. The Golden State is considering legislation barring the use of the "personal...
MRK: 57.60 (+0.09), GSK: 46.59 (+0.28)
7 Top Dividend Sector Dogs Fetch 24% To 50% April Upsides
Fredrik Arnold - at Seeking Alpha - Fri Apr 24, 5:23PM CDT
NMFC: 14.93 (-0.03), RSO: 4.50 (+0.01), TIS: 22.16 (-1.43), NMM: 13.04 (+0.13), CPLP: 9.61 (+0.16), PER: 8.12 (+0.15), SFL: 15.63 (-0.01), TICC: 6.86 (-0.03), CNSL: 21.30 (+0.12), GSK: 46.59 (+0.28), WIN: 7.83 (-0.46), DSWL: 1.91 (unch), CPAC: 6.98 (-0.03), STB: 5.70 (-0.01), RIG: 16.40 (-0.57), MAT: 30.20 (+1.28), ARR: 3.16 (-0.02), XIN: 3.44 (-0.08), WMC: 14.91 (+0.07), SPKE: 13.00 (-0.04)
'Non-Cyclical Consumer Healthcare': How This Sector Will Create Long-Term Wealth
Peter Mantas - Seeking Alpha - Fri Apr 24, 1:39PM CDT
Allow me to provide you with a hypothetical portfolio containing only 5 stocks. This portfolio is somewhat diversified in that each company operates in different markets with different threats, competitors and opportunities, but all 5 companies have...
MCK: 229.20 (+0.09), AKRX: 55.24 (-0.68), PFE: 35.27 (-0.09), EW: 138.33 (-3.59), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), MOH: 63.85 (-0.13), ORCL: 43.08 (-0.31), CNC: 73.67 (+1.13), JNJ: 101.08 (+0.62), ANTM: 154.28 (+0.08), VRSK: 72.68 (+0.20), GILD: 103.69 (-1.52), RMD: 65.70 (-7.68), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), FICO: 93.85 (+0.55), WCN: 46.52 (+0.32), SRCL: 136.94 (-3.56), SNY: 51.75 (-0.01), ACN: 93.40 (-0.44), NVS: 104.28 (-1.22)
Why Agenus Inc. Shares Are Soaring Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 24, 1:04PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Agenus shot higher by more...
AGEN: 7.12 (+0.75), INCY: 107.34 (-0.51), GSK: 46.59 (+0.28)
Zofran Nationwide Class Action Lawsuit Under Consideration By Moll Law Group
PR Newswire - Fri Apr 24, 12:18PM CDT
A Chicago law firm said today it is considering filing the first nationwide class action lawsuit against GlaxoSmithKline (GSK), the makers of Zofran, a powerful anti-nausea drug alleged to increase the risk of birth defects when used by pregnant women, particularly during the first trimester.
GSK: 46.59 (+0.28)
No Hiding From Respirageddon For Boehringer
EP Vantage - Seeking Alpha - Fri Apr 24, 11:49AM CDT
Given the hammering that US prices of respiratory drugs have taken as payers assaulted GlaxoSmithKline ’s (NYSE: GSK ) Advair it might come as a shock that sales of Boehringer Ingelheim ’s blockbuster Spiriva fell just...
ABBV: 66.07 (+1.82), GSK: 46.59 (+0.28)
High-Yield Placeholders For Dividend Champions
Fast Track to Financial Independence - at Seeking Alpha - Fri Apr 24, 10:29AM CDT
KO: 40.89 (-0.06), MMM: 158.99 (-0.67), HTGC: 13.97 (-0.09), MAIN: 31.39 (+0.09), SDIV: 24.18 (+0.22), ED: 62.50 (+0.40), TGH: 31.32 (unch), GSK: 46.59 (+0.28), BNS: 54.97 (-0.01), MORL: 20.47 (+0.08), STWD: 24.27 (+0.10), T: 34.01 (-0.22), JNJ: 101.08 (+0.62), OHI: 38.53 (+0.24), PFF: 40.05 (+0.01), PG: 81.00 (+0.05), AIG: 56.99 (+0.24), AAPL: 130.28 (+0.61), BBL: 47.75 (+1.40), GAIN: 7.56 (-0.03)
Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 9:00AM CDT
Novartis' core earnings earnings per share came in at $1.33, down from $1.35 in the year-ago period but above the Zacks Consensus Estimate of $1.09.
SHPG: 255.11 (-0.26), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Glaxo's malaria vaccine candidate reduced cases in young children 36% in study
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 8:34AM CDT
GSK: 46.59 (+0.28)
GSK's Malaria Vaccine Phase 3 Study Containing Agenus' QS-21 Published in The Lancet
Business Wire - Fri Apr 24, 6:00AM CDT
--EMA currently reviewing the regulatory application
AGEN: 7.12 (+0.75), GSK: 46.59 (+0.28)
Novartis EPS beats the Street
at Investor's Business Daily - Thu Apr 23, 5:33PM CDT
The drugmaking giant earned $1.29 a share in Q1, up 0.8% from a year earlier, beating views by 19 cents. Novartis' (NVS) net profit quadrupled to $13 bil due to gains on sales of units to Eli Lilly (LLY) and GlaxoSmithKline (GSK). Revenue fell 15% to...
LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Isis Pharmaceuticals' ISIS-TTR Effective in Extension Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 5:21PM CDT
Isis Pharmaceuticals, Inc. (ISIS) announced positive data from an extension study on ISIS-TTR for familial amyloid polyneuropathy.
BIIB: 401.71 (-28.57), ISIS: 66.37 (-1.38), AVEO: 1.92 (-0.08), GSK: 46.59 (+0.28)
Novartis (NVS) Beats on Earnings & Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 2:05AM CDT
Novartis (NVS) Beats on Earnings & Revenues
GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Divestment gains boost net earnings at drug company Novartis
AP - Thu Apr 23, 1:57AM CDT
FRANKFURT, Germany (AP) — Swiss-based pharmaceutical company Novartis reported a large jump in first-quarter net profit Thursday as it recorded one-time gains from deals with other drug companies.
LLY: 71.58 (-0.82), GSK: 46.59 (+0.28)
SmarTrend Watching for Potential Rebound in Shares of GlaxoSmithKline After 1.42% Loss
Comtex SmarTrend(R) - Wed Apr 22, 4:37PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $46.43 to a high of $46.90. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $47.00 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 46.59 (+0.28)
GlaxoSmithKline Falls 1.42% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Apr 22, 4:37PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $46.43 to a high of $46.90. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $47.00 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 46.59 (+0.28)
Moll Law Group Considering First Nationwide Class Action Suit Against Maker Of Anti-Nausea Drug Zofran
PR Newswire - Wed Apr 22, 11:15AM CDT
A Chicago law firm said today it is considering filing the first nationwide class action suit against GlaxoSmithKline (GSK), the makers of Zofran, a powerful anti-nausea drug alleged to increase the risk of birth defects when used by pregnant women, particularly during the first trimester.
GSK: 46.59 (+0.28)
GlaxoSmithKline (GSK) Roof Leaking Today
at The Street - Wed Apr 22, 9:21AM CDT
Trade-Ideas LLC identified GlaxoSmithKline (GSK) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
GSK: 46.59 (+0.28)
Rising Rates? Don't Hold Your Breath
Yieldpig - at Seeking Alpha - Wed Apr 22, 4:32AM CDT
HTGC: 13.97 (-0.09), MAT: 30.20 (+1.28), GSK: 46.59 (+0.28)
Rhabdomyosarcoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 22, 3:50AM CDT
The report "Rhabdomyosarcoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Rhabdomyosarcoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/rhabdomyosar...eport.html.
MACK: 13.42 (-0.25), GSK: 46.59 (+0.28), CELGZ: 2.76 (-0.12)
